Your current location:Home

      Zhejiang Huajun Pharmaceutical Co., Ltd., ( hereinafter called Huajun pharma) a holding subsidiary of Zhejiang Huadi Pharmaceutical Group Co., Ltd., was established in December 2015 with a registered capital of 50 million yuan. In line with the tenet of people-oriented, health promotion, Huajun Pharma is mainly engaged in the research and development, production and sales of new products in the field of biopharmaceuticals. In November 2018, Huajun Pharma was recognized as a high-tech enterprise.

      Huajun pharma focuses on the production of synthetic peptide APIs,customized peptides, biochemical extracts and multi-component biochemical drugs. The representative products of synthetic peptides include: thymopentin, oxytocin, octreotide, Lanreotide, Triptorelin, Leuprorelin etc. Biochemical extraction products include: Cerebroprotein hydrolysate, Ribonucleic acid, Thymosin peptide, Chymotrypsin, Hepatocyte growth promoting factor (suckling pig liver extract), etc.

      Huajun pharma has Chinese GMP production line and R&D Center for synthetic polypeptide raw materials. It's also equipped with plant, equipment/facilities, storage area, air conditioning purification system and purified water preparation system which is suitable for drug production. And there are trained and qualified production personnel, inspectors with technical ability to meet the production requirements.

      Huajun pharma has a high-level R&D team who has developed a number of small molecule polypeptide products with independent intellectual property rights. It also has three authorized patents. Other three patents are in process. At present, more than 10 new products and projects have been launched, and about 10 patents are expected to be launched in the future. Later, we will intensify R&D efforts, open up multiple channels, constantly innovate products, and create leading brands. Efforts will be made to build the enterprise into a first-class domestic within five years, to achieve the vision of 'sustainable development, leading peers'.